Ani Pharmaceuticals (ANIP) Capital Expenditures Growth (3y) (2013 - 2026)
Powered by 
Analysis
Ani Pharmaceuticals (ANIP) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | -4.39% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | -8.00% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 6.51% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 36.75% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 40.10% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 6.89% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | -1.73% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.89% |
| Mar 31, 2026 | 37.26% |
| Dec 31, 2025 | -26.54% |
| Sep 30, 2025 | 35.23% |
| Jun 30, 2025 | 44.84% |
| Mar 31, 2025 | 8.28% |
| Dec 31, 2024 | 88.75% |
| Sep 30, 2024 | 103.50% |
| Jun 30, 2024 | 68.38% |
| Mar 31, 2024 | 87.23% |
| Dec 31, 2023 | 2.60% |
| Sep 30, 2023 | -0.42% |
| Jun 30, 2023 | 51.10% |
| Mar 31, 2023 | 15.14% |
| Dec 31, 2022 | 22.60% |
| Sep 30, 2022 | 17.46% |
| Jun 30, 2022 | -6.84% |
| Mar 31, 2022 | 3.17% |
| Dec 31, 2021 | -29.29% |
| Sep 30, 2021 | -25.34% |